Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
16 / 777 trials
PostedSponsorStudyPhaseStatus
16 Nov 2026Dexa Medica GroupIndonesiaThe Efficacy and Safety of DLBS1442 in Patients With Primary DysmenorrheaPhase 2, Phase 3Recruiting13 Nov 2026Novatek PharmaceuticalsA Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Phase 2, Phase 3Not Yet Recruiting13 Nov 2026RemeGen Co., Ltd.ChinaRC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ AdenocarcinomaPhase 2, Phase 3Not Yet Recruiting12 Nov 2026AbbVieA Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.Phase 2, Phase 3Not Yet Recruiting9 Nov 2026Mighty Therapeutics Inc.A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)Phase 2, Phase 3Not Yet Recruiting6 Nov 2026SanofiPhase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and TolerabilityPhase 2, Phase 3Not Yet Recruiting6 Nov 2026United TherapeuticsUnited StatesAn Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)Phase 2, Phase 3Not Yet Recruiting5 Nov 2026Merck Sharp & Dohme LLCA Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Phase 2, Phase 3Not Yet Recruiting5 Nov 2026Teva Branded Pharmaceutical Products R&D LLCTwo Trials to Evaluate TEV-53408 in Participants With Non-Segmental VitiligoPhase 2, Phase 3Not Yet Recruiting2 Nov 2026Enanta Pharmaceuticals, IncUnited StatesA Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePhase 2, Phase 3Recruiting29 Oct 2026Jiangsu Simcere Pharmaceutical Co., Ltd.A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic StrokePhase 2, Phase 3Not Yet Recruiting28 Oct 2026Biohaven Therapeutics Ltd.An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' DiseasePhase 2, Phase 3Not Yet Recruiting28 Oct 2026Ray Therapeutics, Inc.United StatesStudy to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)Phase 2, Phase 3Recruiting22 Oct 2026AVEO Pharmaceuticals, Inc.Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLCPhase 2, Phase 3Not Yet Recruiting21 Oct 2026Azafaros B.V.Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersPhase 2, Phase 3Not Yet Recruiting20 Oct 2026GC Biopharma CorpSouth KoreaClinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or OlderPhase 2, Phase 3Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.